Tweedy Browne Co LLC Acquires Shares of 2,696 Elevance Health, Inc. $ELV

Tweedy Browne Co LLC acquired a new position in shares of Elevance Health, Inc. (NYSE:ELV) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 2,696 shares of the company’s stock, valued at approximately $871,000.

Several other large investors have also recently added to or reduced their stakes in ELV. Vanguard Group Inc. increased its position in Elevance Health by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock worth $7,431,322,000 after purchasing an additional 141,747 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Elevance Health by 4.8% in the 3rd quarter. Wellington Management Group LLP now owns 6,621,297 shares of the company’s stock valued at $2,139,473,000 after buying an additional 303,099 shares during the period. Artisan Partners Limited Partnership boosted its stake in shares of Elevance Health by 24.5% in the third quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock valued at $1,478,857,000 after buying an additional 901,626 shares in the last quarter. First Eagle Investment Management LLC grew its holdings in Elevance Health by 25.0% during the third quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock worth $1,292,029,000 after acquiring an additional 798,457 shares during the period. Finally, Norges Bank purchased a new position in Elevance Health in the second quarter worth $1,148,379,000. 89.24% of the stock is owned by hedge funds and other institutional investors.

Elevance Health Price Performance

Shares of NYSE ELV opened at $296.14 on Wednesday. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70. The stock has a market cap of $65.36 billion, a price-to-earnings ratio of 11.79, a PEG ratio of 1.60 and a beta of 0.51. The company’s 50-day moving average price is $335.31 and its 200 day moving average price is $334.16. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $458.75.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating the consensus estimate of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The business had revenue of $49.31 billion for the quarter, compared to analyst estimates of $49.52 billion. During the same period in the prior year, the business earned $3.84 earnings per share. The company’s quarterly revenue was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, research analysts forecast that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be given a dividend of $1.72 per share. The ex-dividend date of this dividend is Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 annualized dividend and a yield of 2.3%. Elevance Health’s dividend payout ratio (DPR) is 27.39%.

Analyst Ratings Changes

A number of research firms have recently weighed in on ELV. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $332.00 price target on shares of Elevance Health in a research note on Thursday, January 29th. Wall Street Zen lowered shares of Elevance Health from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Robert W. Baird increased their target price on shares of Elevance Health from $297.00 to $340.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. Wolfe Research set a $425.00 price target on Elevance Health and gave the stock an “outperform” rating in a research note on Thursday, January 8th. Finally, UBS Group set a $400.00 price target on Elevance Health in a report on Thursday, January 29th. Twelve equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Elevance Health has a consensus rating of “Moderate Buy” and an average price target of $387.40.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.